Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analyst consensus is “Moderate Buy”: Six of eight analysts rate Whitehawk Therapeutics a buy, while one rates it a hold and one a sell. The average 12-month price target is $8.20, above the stock’s recent price of $4.11.
• Institutional ownership is substantial: Hedge funds and other institutional investors own 52.08% of the company, with several investors recently increasing or initiating positions.
• Recent earnings exceeded expectations: Whitehawk reported a quarterly loss of $0.20 per share, beating the consensus estimate of a $0.30 loss. Analysts expect a full-year loss of approximately $1.10 per share.

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $8.20.

A number of research analysts recently weighed in on the stock. Wall Street Zen raised shares of Whitehawk Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. Leerink Partners started coverage on Whitehawk Therapeutics in a research note on Monday, July 13th. They set an "outperform" rating and a $9.00 price objective for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Whitehawk Therapeutics in a report on Wednesday, September 2nd. Finally, B. Riley Financial initiated coverage on Whitehawk Therapeutics in a research note on Thursday, June 25th. They issued a "buy" rating and a $10.00 price target on the stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Montanova Capital LLC boosted its stake in Whitehawk Therapeutics by 16.2% during the 2nd quarter. Montanova Capital LLC now owns 4,300,000 shares of the company's stock worth $19,694,000 after purchasing an additional 600,000 shares during the last quarter. Orbimed Advisors LLC purchased a new stake in Whitehawk Therapeutics during the 3rd quarter valued at about $7,915,000. Acuta Capital Partners LLC acquired a new stake in Whitehawk Therapeutics in the 3rd quarter valued at about $6,480,000. KVP Capital Advisors LP acquired a new stake in Whitehawk Therapeutics in the 4th quarter valued at about $5,242,000. Finally, Yu Fan purchased a new position in Whitehawk Therapeutics in the 3rd quarter worth approximately $3,933,000. Hedge funds and other institutional investors own 52.08% of the company's stock.

Whitehawk Therapeutics Stock Performance

Whitehawk Therapeutics stock opened at $4.11 on Friday. The stock has a market capitalization of $234.31 million, a P/E ratio of -3.67 and a beta of 0.81. The company's fifty day moving average price is $4.29 and its 200 day moving average price is $4.10. Whitehawk Therapeutics has a 1 year low of $1.80 and a 1 year high of $5.49.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.10. Sell-side analysts predict that Whitehawk Therapeutics will post -1.1 EPS for the current year.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.